To ask the Secretary of State for Health how many medicines have been assessed by the National Institute for Health and Clinical Excellence under end-of-life criteria since it was established.
Information on published appraisals to which a National Institute for Health and Clinical Excellence Appraisal Committee applied the flexibility for the appraisal of potentially life extending treatments for patients at the end of their lives is shown in the table.
|Publication date||Appraisal title||Recommendation1|
|March 2009||Sunitinib for the first line treatment of advanced and/or metastatic renal cell carcinoma||Recommended|
|June 2009||Lenalidomide for the treatment of multiple myeloma||Recommended|
|August 2009||Sorafenib for the first and second-line treatment of advanced and/or metastatic renal cell carcinoma||Not recommended|
|Temsirolimus for the first-line treatment of advanced and/or metastatic renal cell carcinoma||Not recommended|
|September 2009||Sunitinib for the treatment of gastrointestinal stromal tumours||Recommended|
|November 2009||Topotecan for the treatment of lung cancer (small-cell)||Recommended|
|February 2010||Trabectedin for soft tissue sarcoma||Recommended|
|May 2010||Sorafenib for the treatment of hepatocellular carcinoma||Not recommended|
|June 2010||Pemetrexed for the maintenance treatment of non-small-cell lung cancer||Recommended|
| Note: |
Where a treatment is "recommended", it is recommended in line with the marketing authorisation or in line with clinical practice.